Light Sciences Oncology is developing Light Infusion Therapy (Litx™), an innovative light-activated treatment for solid tumors. LSO is currently developing Litx™ for the treatment of patients with cancers such as hepatoma, metastatic colorectal cancer and glioma, for  which the current therapeutic alternatives are of limited efficacy. Litx™ has been designed to treat a wide range of solid tumors, including previously treated or untreatable tumors, and to be used repeatedly throughout a patient's life as needed. LSO’s goal is to enable physicians to use Litx™ to treat cancer as a chronic disease. Treatment of patients with hepatoma has begun in a Phase III trial, the final trial required by the U.S. Food and Drug Administration prior to commercial registration of a drug. Patient treatments in a Phase III trial for metastatic colorectal cancer and a Phase II trial for glioma have also commenced. A Phase III trial for glioma is scheduled to begin in mid 2007.